Synthesis and pharmacological testing of polyaminoquinolines as blockers of the apamin-sensitive Ca2+-activated K+ channel (SKCa)

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 16, 2007, Pages 5457-5479

  Fletcher, David I ^a   Ganellin, C Robin ^a   Piergentili, Alessandro ^a   Dunn, Philip M ^a   Jenkinson, Donald H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

After hyperpolarization; AHP; Aminoquinoline; Apamin; Calcium activated; Guanidine; Potassium ion channel; Quinoline; SK3; SKCa

Indexed keywords

1,2,3 TRIS[3 (4 QUINOLINYLAMINO)PROPOXY]BENZENE; 1,2,3 TRIS[3 [4 (N ETHYL)QUINOLINIUMYLAMINO]PROPOXY]BENZENE TRIIODIDE; 4,4' BIS(GUANIDINOMETHYL)STILBENE TRIFLUOROACETATE; APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; FUMARIC ACID; GUANIDINE DERIVATIVE; N (3 GUANIDINOPROPYL) N (8 AMINOOCTYL) 3 [(N' (N'' 3 GUANIDINOPROPYL)CARBAMOYL)]PROPENAMIDE TRINITRATE; N (3 GUANIDINOPROPYL) N (8 AMINOOCTYL) 3 [N' (N'' 3 GUANIDINOPROPYL)CARBAMOYL]PROPENAMIDE TRINITRATE; N (3 GUANIDINOPROPYL) N [4 (4' AMINOMETHYLPHENYL)]BENZYL 3 N'' (3 GUANIDINOPROPYL)CARBAMOYLPROPENAMIDE TRINITRATE; N (4 QUINOLINYL) 3,4 BIS[3 (4 QUINOLINYLAMINO)PROPOXY]PHENETHYLAMINE; N [3 (4 QUINOLINYL)AMINOPROPYL] N (8 AMINOOCTYL) 3 N' [3 (4 QUINOLINYL)AMINOPROPYL]CARBAMOYLPROPENAMIDE; N [3 (4 QUINOLINYLAMINO)PROPYL] 3,5 BIS[3 (4 QUINOLINYLAMINO)PROPOXY]ANILINE; N [3 (4 QUINOLINYLAMINO)PROPYL] 3,5 BIS[3 (4 QUINOLINYLAMINO)PROPOXY]BENZYLAMINE; N [3 (4 QUINOLINYLAMINO)PROPYL] N [5 (4 QUINOLINYLAMINO)PENTYL 3,5BIS[3 (4 QUINOLINYLAMINO)PROPOXY]ANILINE; N [3 (4 QUINOLINYLAMINO)PROPYL] N [5 (4 QUINOLINYLAMINO)PENTYL] 3,5 BIS [3 (4 QUINOLINYLAMINO)PROPOXY]ANILINE; N [3 (4 QUINOLINYLAMINO)PROPYL] N [5 (4 QUINOLINYLAMINO)PENTYL] 3,5 BIS[3 (4 QUINOLINYLAMINO)PROPOXY]ANILINE; N [3 (4 QUINOLINYLAMINO)PROPYL] N [5 (4 QUINOLINYLAMINO)PENTYL] 3,5 BIS[3 (4 QUINOLINYLAMINO)PROPOXY]BENZYLAMINE; POLYAMINOQUINOLINE DERIVATIVE; QUINOLINE DERIVATIVE; UCL 1684; UCL 1848; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE;

AMINOQUINOLINES; ANIMALS; APAMIN; GUANIDINE; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; NEURONS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE CULTURE TECHNIQUES;

RATTUS;

EID: 34250720150     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.05.054     Document Type: Article

References (46)

1. Haylett D.G., and Jenkinson D.H. Calcium-activated potassium channels. In: Cook N.S. (Ed). Potassium Channels (1990), Ellis Horwood, Chichester 70-95
2. Vergara C., Latorre R., Marrion N.V., and Adelman J.P. Curr. Opin. Neurobiol. 8 (1998) 321
3. Castle N.A. Perspect. Drug Discovery Des. 16 (1999) 131
4. Stocker M. Nature Rev. Neurosci. 5 (2004) 758
5. Liégeois J.-F., Mercier F., Graulich A., Graulich-Lorge F., Scuvée-Moreau J., and Seutin V. Curr. Med. Chem. 10 (2003) 625
6. Lawson K., and McKay N.G. Curr. Pharm. Des. 12 (2006) 459
7. Tamarina N.A., Wang Y., Mariotto L., Kuznetsov A., Bond C., Adelman J., and Philipson L.H. Diabetes 52 (2003) 2000
8. Deschaux O., and Bizot J.C. Neurosci. Lett. 386 (2005) 5
9. Hammond R.S., Bond C.T., Strassmaier T., Ngo-Ahn T.J., Adelman J.P., Maylie J., and Stackman R.W. J. Neurosci. 26 (2006) 1844
10. Kohler M., Hirschberg B., Bond C.T., Kinzie J.M., Marrion N.V., Maylie J., and Adelman J.P. Science 273 (1996) 1709
11. Hosseini R., Benton D.C.H., Dunn P.M., Jenkinson D.H., and Moss G.W.J. J. Physiol. 535 (2001) 323
12. Obermair G.J., Kaufmann W.A., Knaus H.G., and Flucher B.E. Eur. J. Neurosci. 17 (2003) 721
13. Banks B.E.C., Brown C., Burgess G.M., Burnstock G., Claret M., Cocks T.M., and Jenkinson D.H. Nature 282 (1979) 415
14. Blatz A.L., and Magleby K.L. Nature 323 (1986) 718
15. Auguste P., Hugues M., Grave B., Gesquiere J.C., Maes P., Tartar A., Romey G., Schweitz H., and Lazdunski M. J. Biol. Chem. 265 (1990) 4753
16. Zerrouk H., Mansuelle P., Benslimane A., Rochat H., and Martin-Eauclaire M.F. FEBS Lett. 320 (1993) 189
17. Jenkinson D.H., Haylett D.G., and Cook N.S. Cell Calcium 4 (1983) 429
18. Nohmi M., and Kuba K. Brain Res. 301 (1984) 146
19. Cook N.S., and Haylett D.G. J. Physiol. 358 (1985) 373
20. Castle N.A., Haylett D.G., Morgan J.M., and Jenkinson D.H. Eur. J. Pharmacol. 236 (1993) 201
21. Galanakis D., Davis C.A., Del Rey Herrero B., Ganellin C.R., Dunn P.M., and Jenkinson D.H. J. Med. Chem. 38 (1995) 595
22. Galanakis D., Davis C.A., Ganellin C.R., and Dunn P.M. J. Med. Chem. 39 (1996) 359
23. Campos R.J., Galanakis D., Piergentili A., Bhandari K., Ganellin C.R., Dunn P.M., and Jenkinson D.H. J. Med. Chem. 43 (2000) 420
24. Chen, J.Q. Galanakis D., Ganellin C.R., Dunn P.M., and Jenkinson D.H. J. Med. Chem. 43 (2000) 3478
25. U.S. Patent 5,866,562, 1999.
26. U.S. Patent 5,874,438, 1999.
27. Graulich A., Scuvée-Moreau J., Alleva L., Lamy C., Waroux O., Seutin V., and Liégeois J.-F. J. Med. Chem. 49 (2006) 7208
28. Galanakis D., Ganellin C.R., Chen J.Q., Gunasekera D., and Dunn P.M. Bioorg. Med. Chem. Lett. 14 (2004) 4231
29. Vincent J.P., Schweitz H., and Lazdunski M. Biochemistry 14 (1975) 2521
30. Labbe-Jullie C., Granier C., Albericio F., Defendini M.-L., Ceard B., Rochat H., and Van Rietschoten J. Eur. J. Biochem. 196 (1991) 639
31. Sabatier J.M., Fremont V., Mabrouk K., Crest M., Darbon H., Rochat H., Vanrietschoten J., and Martin-Eauclaire M.F. Int. J. Pept. Protein Res. 43 (1994) 486
32. Inisan A.G., Meunier S., Fedelli O., Altbach M., Fremont V., Sabatier J.M., Thevan A., Bernassau J.M., Cambillau C., and Darbon H. Int. J. Pept. Protein Res. 45 (1995) 441
33. Sabatier J.M., Zerrouk H., Darbon H., Mabrouk K., Benslimane A., Rochat H., Martin-Eauclaire M.F., and Van Rietschoten J. Biochemistry 32 (1993) 2763
34. Demonchaux P., Ganellin C.R., Dunn P.M., and Jenkinson D.H. Eur. J. Med. Chem. 26 (1991) 915
35. Freeman C.M., Catlow C.R.A., Hemmings A.M., and Hider R.C. FEBS Lett. 197 (1986) 289
36. Campos Rosa J., Galanakis D., Ganellin C.R., and Dunn P.M. J. Med. Chem. 39 (1996) 4247
37. Nolan W.P., Ratcliffe G.S., and Rees D.C. Tetrahedron Lett. 33 (1992) 6879
38. Galanakis D., Ganellin C.R., Dunn P.M., and Jenkinson D.H. Arch. Pharm. Pharm. Med. Chem. 329 (1996) 524
39. Dunn P.M. Eur. J. Pharmacol. 252 (1994) 189
40. Otsubo T., Gray R., and Boekelheide V. J. Am. Chem. Soc. 100 (1978) 2449
41. Galanakis D., Ganellin C.R., Malik S., and Dunn P.M. J. Med. Chem. 39 (1996) 3592
42. Campos Rosa J., Beckwith-Hall B.M., Galanakis D., Ganellin C.R., Dunn P.M., and Jenkinson D.H. Bioorg. Med. Chem. Lett. 7 (1997) 7
43. Byron D.J., Gray G.W., and Wilson R.C. J. Chem. Soc. (C) (1966) 840
44. Dunn P.M., Benton D.C.H., Campos Rosa J., Ganellin C.R., and Jenkinson D.H. Br. J. Pharmacol. 117 (1996) 35
45. Campos Rosa J., Galanakis D., Ganellin C.R., Dunn P.M., and Jenkinson D.H. J. Med. Chem. 41 (1998) 2
46. Davies, K. ChemX Molecular Graphics Programme, developed and distributed by Chemical Design Ltd, Oxford, UK, 1986.